中炬高新(600872.SH):副總經理張衞華、朱洪濱因涉嫌嚴重違法被留置調查
格隆匯2月20日丨中炬高新(600872.SH)公佈,公司於2月17日晚收到中山市監察委員會的兩份《留置通知書》(中山留置通【2023】3號、4號),公司副總經理張衞華、朱洪濱因涉嫌嚴重違法,經廣東省監察委員會批准,中山市監察委員會對兩人立案調查並實施留置。
張衞華,1967年12月出生,1995年起在公司任職,2004年8月起任副總經理。朱洪濱,1968年2月出生,1994年起在公司任職,2012年11月起任副總經理。
截至公吿披露日,公司尚未知悉上述高管被留置的具體原因,公司將持續關注上述事項的後續情況,並嚴格按照有關法律、法規的規定和要求,及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.